NPS Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

21.02.15	Shire Plc Announces Successful Completion NPS Pharma Acquisition - Quick Facts (RTTNews)
26.01.15	New Drug Approvals - The Month That Was (RTTNews)
24.01.15	NPS Pharma Says FDA OKs Natpara For Hypoparathyroidism Treatment - Quick Facts (RTTNews)
12.01.15	SCYX Rises, ARGS Crashes, AMRI Opens Wallet, NPSP Snapped Up, TNXP On Watch (RTTNews)
11.01.15	Shire To Acquire NPS Pharmaceuticals For $5.2 Bln (RTTNews)
11.01.15	Shire To Buy NPS Pharmaceuticals For $5.2 Bln (RTTNews)
06.01.15	NPS Pharma Seeks Buyer : Report (RTTNews)
18.12.14	Shire Considers Bid For NPS Pharma : Report (RTTNews)
02.12.14	NPS Pharma: EMA Initiates Review Of MAA For Natpar - Quick Facts (RTTNews)
11.11.14	NPS Pharma Loss Widens (RTTNews)
16.09.14	FDA Panel Votes For NPS Pharma's Natpara For Hypoparathyroidism Treatment (RTTNews)
15.09.14	FDA Panel Votes In Favor Of NPS Pharm's Natpara For Hypoparathyroidism Treatment (RTTNews)
12.09.14	NPS Pharma Says FDA Advisory Committee To Review Natpara BLA - Quick Facts (RTTNews)
05.08.14	CBMG Does A Deal, FLML Brightening Up, MusclePharm In Shape, Watch Out For NPSP (RTTNews)
30.06.14	NPS: FDA Approves Updated Labelling For Gattex To Include Long-term Benefits (RTTNews)
10.06.14	NPS : FDA Changes Tentative Date Of Advisory Committee Review Of Natpara BLA (RTTNews)
19.02.14	CHTP Gets FDA Nod, NPSP Reverses Loss, DVAX Withdraws HEPLISAV EU Application (RTTNews)
18.02.14	NPS Pharma Posts Q4 Profit - Quick Facts (RTTNews)
03.01.14	NPS Pharma Gets Orphan Drug Designation For Natpara In Europe - Quick Facts (RTTNews)
13.11.13	NPS Pharma: FDA Accepts For Review SNDA For Gattex - Quick Facts (RTTNews)
25.10.13	BABY Makes Big Leap, RIGL's Trial Flops, CLSN Warming Up To HEAT, NPSP On Watch (RTTNews)
21.10.13	Divestiture, Clinical Study Updates, New Drug Application, and Quarterly Report - Research Report on Geron, NPS, Portola, MannKind, and Exact Sciences (PR Newswire)
16.10.13	Dividend Announcements, Earnings Release Scheduled, and Data Presentations from Clinical Studies - Research Report on Questcor, Regeneron, NPS, Incyte, and Nektar (PR Newswire)
15.10.13	Critical Alerts For Ford, NPS Pharmaceuticals, Qualcomm, Delta Air Lines, and Union Pacific Released By InvestorsObserver (PR Newswire)
14.10.13	NPS Pharma Reveals New Data From STEPS 2 Support Long Term Use Of Gattex (RTTNews)
11.10.13	Technical Study: Gilead Sciences Inc., NPS Pharmaceuticals Inc., Halozyme Therapeutics Inc., and InterMune Inc. (PR Newswire)
25.09.13	Data Presentations, FDA Approvals, Board Appointments, Updated Clinical Results and New Contracts - Research Report on Vertex, Celgene, NPS Pharmaceuticals, Cyclacel and BioCryst (PR Newswire)
13.09.13	Critical Alerts For Yahoo, Ctrip, NPS Pharmaceuticals, Krispy Kreme Doughnuts, and Nasdaq Released By InvestorsObserver (PR Newswire)
12.09.13	Technical Study: Gilead Sciences Inc., Halozyme Therapeutics Inc., NPS Pharmaceuticals Inc., and InterMune Inc. (PR Newswire)
14.08.13	Quarterly Results, Collaborations and Product Launches - Research Report on Onyx Pharmaceuticals, Express Scripts, NPS Pharmaceuticals, Salix Pharmaceuticals, and MannKind Corporation (PR Newswire)
13.08.13	Critical Alerts For Yahoo, Adobe, NPS Pharmaceuticals, AngloGold Ashanti, and Monster Beverage Released By InvestorsObserver (PR Newswire)
06.08.13	Early Briefing and Review: Gilead Sciences, InterMune, NPS Pharma, and Halozyme Therapeutics (PR Newswire)
05.08.13	Accretive Collaborations, Strengthened Management, and Earnings Release Schedules - Research Report on Seattle Genetics, Santarus, BioCryst, NPS, and PDL BioPharma (PR Newswire)
06.08.12	NPS Pharmaceuticals Joins the Oley Foundation in Recognizing HPN Awareness Week, August 5-11 (Businesswire)
27.07.12	NPS Pharmaceuticals to Report Second Quarter 2012 Financial Results (Businesswire)
02.07.12	NPS Pharmaceuticals Announces Amended Royalty Agreement with Amgen (Businesswire)
25.06.12	New Findings from REPLACE Study Support Potential of Natpara(TM) to Treat Adult Hypoparathyroidism (Businesswire)
22.06.12	Takeda Receives Positive CHMP Opinion for Teduglutide (Revestive®) for Patients with Short Bowel Syndrome (Businesswire)
18.06.12	NPS Pharmaceuticals Reports NatparaTM Phase 3 Results to be Presented at ENDO, the annual meeting of The Endocrine Society (Businesswire)
01.06.12	NPS Pharmaceuticals Joins the Hypoparathyroidism Association in Recognition of World Hypoparathyroidism Awareness Day (Businesswire)
29.05.12	NPS Pharmaceuticals to Present at Jefferies Global Healthcare Conference (Businesswire)
21.05.12	Digestive Disease Week Presentations Support Therapeutic Potential for Gattex (teduglutide) as Novel Treatment for Adult Short Bowel Syndrome (Businesswire)
03.05.12	NPS Pharmaceuticals Reports First Quarter 2012 Financial Results (Businesswire)
03.05.12	NPS Pharmaceuticals Reports Four Additional Patients Achieve Independence from Parenteral Support in STEPS 2 Study of Gattex® in Adult Short Bowel Syndrome (Businesswire)
27.04.12	NPS Pharmaceuticals to Report First Quarter 2012 Financial Results (Businesswire)
26.04.12	NPS Pharmaceuticals Among 100 Best Places to Work in New Jersey (Businesswire)
27.03.12	NPS Pharmaceuticals to Present at Needham Healthcare Conference (Businesswire)
07.03.12	NPS Pharmaceuticals to Present at Barclays Capital Global Healthcare Conference (Businesswire)
29.02.12	NPS Pharmaceuticals Appoints Georges Gemayel, Ph.D., to Board of Directors (Businesswire)
27.02.12	NPS Pharmaceuticals Observes Rare Disease Day 2012 (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

ABB	50.28	1.62 %	K V
UBS Group	28.48	1.42 %	K V
CieFinRichemont	122.70	1.24 %	K V
Lonza Grp	526.40	1.15 %	K V
Part Grp Hldg	1’280.00	1.11 %	K V
Sonova Hldg	300.80	-0.07 %	K V
Sika	228.10	-0.09 %	K V
Novartis	93.27	-0.12 %	K V
Nestle	76.48	-0.21 %	K V
Swisscom	508.50	-0.29 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu NPS Pharmaceuticals Inc.

Aktien Top/Flop

Meistgelesene Nachrichten